Prognostic factors for 30-d survival in patients with newly diagnosed APL
| . | . | . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| Features . | n . | 30-d survival (%) . | P . | HR . | 95% CI . | P . | HR . | 95% CI . |
| Patients, n | 358 | 84.4 | — | — | — | — | — | — |
| Period of diagnosis | ||||||||
| 2007-2012 | 158 | 81 | .16 | 1.46 | 0.86-2.47 | — | — | — |
| 2013-2020 | 200 | 87 | — | 0.69 | 0.41-1.16 | — | — | — |
| Sex | ||||||||
| Male | 173 | 79.8 | .02 | 1.88 | 1.10-3.23 | .01 | 2.32 | 1.26-4.28 |
| Female | 185 | 88.6 | — | 0.53 | 0.31-0.91 | — | 0.43 | 0.23-0.79 |
| Age at diagnosis, y | ||||||||
| ≥50 | 171 | 82.5 | .01 | 2.10 | 1.21-3.61 | .09 | 1.66 | 0.93-2.98 |
| <50 | 187 | 89.3 | — | 0.48 | 0.28-0.83 | — | 0.60 | 0.34-1.10 |
| Institution at initial presentation | ||||||||
| Regional hospital | 306 | 83.0 | .11 | 2.29 | 0.83-6.33 | — | — | — |
| QMH | 52 | 92.3 | — | 0.44 | 0.16-1.21 | — | — | — |
| Hematologic features at presentation | ||||||||
| Hemoglobin, g/dL | ||||||||
| ≥8 | 203 | 86.2 | .30 | 0.76 | 0.45-1.28 | — | — | — |
| <8 | 155 | 81.9 | — | 1.32 | 0.78-2.23 | — | — | — |
| Leucocyte count, ×109/L | ||||||||
| ≥10 | 129 | 76.0 | <.001 | 2.80 | 1.64-4.76 | .03 | 1.93 | 1.05-3.54 |
| <10 | 229 | 90.0 | — | 0.36 | 0.21-0.61 | — | 0.52 | 0.28-0.95 |
| Platelet count, ×109/L | ||||||||
| ≥40 | 119 | 87.4 | .25 | 0.71 | 0.39-1.27 | — | — | — |
| <40 | 239 | 82.8 | — | 1.42 | 0.78-2.56 | — | — | — |
| PT, s | ||||||||
| ≥16 | 99 | 69.7 | <.001 | 3.64 | 2.14-6.18 | .052 | 1.88 | 1.00-3.53 |
| <16 | 254 | 90.2 | — | 0.28 | 0.16-0.47 | — | .53 | 0.28-1.00 |
| APTT, s | ||||||||
| ≥40 | 12 | 58.3 | .02 | 3.10 | 1.23-7.78 | .20 | 1.85 | 0.72-4.76 |
| <40 | 341 | 85.3 | — | 0.32 | 0.13-0.81 | — | 0.54 | 0.21-1.39 |
| Fibrinogen, g/L | ||||||||
| ≥1.5 | 158 | 91.1 | .002 | 0.38 | 0.20-0.71 | .02 | 0.47 | 0.24-0.90 |
| <1.5 | 163 | 78.5 | — | 2.63 | 1.42-4.90 | — | 2.15 | 1.11-4.14 |
| Timing of ATRA administration | ||||||||
| 0-24 h of presentation | 287 | 87.8 | .001 | 0.38 | 0.22-0.66 | <.001 | 0.32 | 0.18-0.57 |
| >24 h after presentation | 71 | 70.4 | — | 2.61 | 1.52-4.48 | — | 3.16 | 1.75-5.69 |
| . | . | . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| Features . | n . | 30-d survival (%) . | P . | HR . | 95% CI . | P . | HR . | 95% CI . |
| Patients, n | 358 | 84.4 | — | — | — | — | — | — |
| Period of diagnosis | ||||||||
| 2007-2012 | 158 | 81 | .16 | 1.46 | 0.86-2.47 | — | — | — |
| 2013-2020 | 200 | 87 | — | 0.69 | 0.41-1.16 | — | — | — |
| Sex | ||||||||
| Male | 173 | 79.8 | .02 | 1.88 | 1.10-3.23 | .01 | 2.32 | 1.26-4.28 |
| Female | 185 | 88.6 | — | 0.53 | 0.31-0.91 | — | 0.43 | 0.23-0.79 |
| Age at diagnosis, y | ||||||||
| ≥50 | 171 | 82.5 | .01 | 2.10 | 1.21-3.61 | .09 | 1.66 | 0.93-2.98 |
| <50 | 187 | 89.3 | — | 0.48 | 0.28-0.83 | — | 0.60 | 0.34-1.10 |
| Institution at initial presentation | ||||||||
| Regional hospital | 306 | 83.0 | .11 | 2.29 | 0.83-6.33 | — | — | — |
| QMH | 52 | 92.3 | — | 0.44 | 0.16-1.21 | — | — | — |
| Hematologic features at presentation | ||||||||
| Hemoglobin, g/dL | ||||||||
| ≥8 | 203 | 86.2 | .30 | 0.76 | 0.45-1.28 | — | — | — |
| <8 | 155 | 81.9 | — | 1.32 | 0.78-2.23 | — | — | — |
| Leucocyte count, ×109/L | ||||||||
| ≥10 | 129 | 76.0 | <.001 | 2.80 | 1.64-4.76 | .03 | 1.93 | 1.05-3.54 |
| <10 | 229 | 90.0 | — | 0.36 | 0.21-0.61 | — | 0.52 | 0.28-0.95 |
| Platelet count, ×109/L | ||||||||
| ≥40 | 119 | 87.4 | .25 | 0.71 | 0.39-1.27 | — | — | — |
| <40 | 239 | 82.8 | — | 1.42 | 0.78-2.56 | — | — | — |
| PT, s | ||||||||
| ≥16 | 99 | 69.7 | <.001 | 3.64 | 2.14-6.18 | .052 | 1.88 | 1.00-3.53 |
| <16 | 254 | 90.2 | — | 0.28 | 0.16-0.47 | — | .53 | 0.28-1.00 |
| APTT, s | ||||||||
| ≥40 | 12 | 58.3 | .02 | 3.10 | 1.23-7.78 | .20 | 1.85 | 0.72-4.76 |
| <40 | 341 | 85.3 | — | 0.32 | 0.13-0.81 | — | 0.54 | 0.21-1.39 |
| Fibrinogen, g/L | ||||||||
| ≥1.5 | 158 | 91.1 | .002 | 0.38 | 0.20-0.71 | .02 | 0.47 | 0.24-0.90 |
| <1.5 | 163 | 78.5 | — | 2.63 | 1.42-4.90 | — | 2.15 | 1.11-4.14 |
| Timing of ATRA administration | ||||||||
| 0-24 h of presentation | 287 | 87.8 | .001 | 0.38 | 0.22-0.66 | <.001 | 0.32 | 0.18-0.57 |
| >24 h after presentation | 71 | 70.4 | — | 2.61 | 1.52-4.48 | — | 3.16 | 1.75-5.69 |